M&A Deal Summary

Shionogi & Co Acquires Tetra Therapeutics

On May 26, 2020, Shionogi & Co acquired life science company Tetra Therapeutics

Acquisition Highlights
  • This is Shionogi & Co’s 1st transaction in the Life Science sector.
  • This is Shionogi & Co’s 1st transaction in the United States.
  • This is Shionogi & Co’s 1st transaction in Michigan.

M&A Deal Summary
Date 2020-05-26
Target Tetra Therapeutics
Sector Life Science
Buyer(s) Shionogi & Co
Deal Type Add-on Acquisition

Target

Tetra Therapeutics

Grand Rapids, Michigan, United States
Tetra Therapeutics is a clinical-stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. Tetra Therapeutics is based in Grand Rapids, Michigan.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Shionogi & Co

Osaka, Japan
Category Company
Founded 1878
Sector Manufacturing
Employees5,693
Revenue 435.1B JPY (2024)
DESCRIPTION

Shionogi & Co is a pharmaceutical company develops crestor, medical supply and brand name also uses Shionogi. Shionogi was founded in 1878 and is based in Osaka, Japan.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 3 of 3
State (Michigan) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-08-01 C&O Pharmaceutical Technology Holdings

Tsim Sha Tsui, China

C&O is an integrated pharmaceutical group in China. Its activities span research & development, manufacturing, and marketing and distribution of C&O and third party brand products.

Buy $185M
Mergr

Product

Company

Legal